Dyadic International (DYAI) Free Cash Flow (2018 - 2026)
Dyadic International (DYAI) posted Free Cash Flow of -$2.0 million for Q1 2026, down 10.92% sequentially from -$1.8 million in Q4 2025, and down 0.7% YoY from -$2.0 million in Q1 2025.
Dyadic International (DYAI) Free Cash Flow (2018 - 2026) Analysis & Trends
Dyadic International has reported Free Cash Flow for 9 years, with the latest figure at -$2.0 million in Q1 2026.
- Quarterly Free Cash Flow fell 0.7% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.7 million (down 18.79% YoY) and the FY2025 annual result came in at -$5.7 million, down 43.46% from the prior year.
- Free Cash Flow declined to -$2.0 million in Q1 2026 per DYAI's latest filing, from -$1.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$130015.0 in Q2 2025 and troughed at -$2.9 million in Q1 2022.
- A 5-year average of -$1.6 million and a median of -$1.8 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow surged 99.85% in 2022, then slumped 821.31% in 2025.
- Over 5 years, Free Cash Flow stood at -$1.7 million in 2022, then soared by 45.09% to -$923380.0 in 2023, then gained by 24.58% to -$696395.0 in 2024, then tumbled by 154.18% to -$1.8 million in 2025, then declined by 10.92% to -$2.0 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$2.0 million, -$1.8 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | -1.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.96 Mn |
| Mar 31, 2026 | -1.96 Mn |
| Dec 31, 2025 | -1.77 Mn |
| Dec 31, 2025 | -1.77 Mn |
| Sep 30, 2025 | -1.85 Mn |
| Sep 30, 2025 | -1.85 Mn |
| Jun 30, 2025 | -130,015.00 |
| Jun 30, 2025 | -130,015.00 |
| Mar 31, 2025 | -1.95 Mn |
| Mar 31, 2025 | -1.95 Mn |
| Dec 31, 2024 | -696,395.00 |
| Dec 31, 2024 | -696,395.00 |
| Sep 30, 2024 | -201,057.00 |
| Sep 30, 2024 | -201,057.00 |
| Jun 30, 2024 | -1.96 Mn |
| Jun 30, 2024 | -1.96 Mn |
| Mar 31, 2024 | -1.11 Mn |
| Mar 31, 2024 | -1.11 Mn |
| Dec 31, 2023 | -923,380.00 |
| Dec 31, 2023 | -923,380.00 |